Stroke care company Imperative Care Inc revealed on Friday the appointment of Daniel Davis as its chief operating officer.
In the senior position in the company, Davis is responsible for the launch and growth of the breakthrough technologies to treat ischemic stroke patients in the US.
Most recently, Davis has served as chief commercial officer and president of North America, Penumbra, where he launched the first FDA-cleared aspiration system for neurovascular mechanical thrombectomy.
The company said Davis brings 19 years of experience in sales, marketing, and business development with both early stage and Fortune 500 medical device, technology and consumer product companies, focused on bringing neurovascular innovations to market.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach